Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 8, Number 6, December 2017, pages 319-326


Subcutaneous Implantable Cardioverter Defibrillators Implantation Without Defibrillation Threshold Testing: A Single Center Experience

Figures

Figure 1.
Figure 1. Outcomes comparison of S-ICD and TV-ICD: survival. Kaplan-Meier plot of survival in the S-ICD and TV-ICD patients. S-ICD: subcutaneous implantable cardioverter defibrillators; TV-ICD: transvenous implantable cardioverter defibrillators.
Figure 2.
Figure 2. Outcomes comparison of S-ICD and TV-ICD therapy: device-related complications. Kaplan-Meier plot of device-related complications in the S-ICD and TV-ICD patients. S-ICD: subcutaneous implantable cardioverter defibrillators; TV-ICD: transvenous implantable cardioverter defibrillators.

Table

Table 1. Baseline Clinical Characteristics of the S-ICD and TV-ICD Patients
 
Patient characteristicsS-ICD, N (%)TV-ICD, N (%)P value
CABG: coronary artery bypass surgery; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; N: number; NYHA: New York Heart Association; S-ICD: subcutaneous implantable cardioverter defibrillators; TV-ICD: transvenous implantable cardioverter defibrillators.
Mean age (years)41.0350.330.009
Male (%)23 (76.7%)24 (80%)0.754
Mean LVEF (%)30.5028.170.405
Primary prevention25 (83%)26 (86.7%)0.718
Diagnosis
  Ischemic heart disease11 (36.7%)14 (46.7%)0.432
  Non-ischemic cardiomyopathy10 (33.3%)14 (46.7%)0.292
  Genetic (inherited) arrhythmia disease4 (13.3%)2 (6.7%)0.389
  Congenital heart disease5 (16.7%)0 (0%)0.020
  Diabetes6 (20%)16 (53.3%)0.007
  Hypertension7(23.3%)16 (53.3%)0.017
  Myocardial infarction10 (33.3%)10 (33.3%)1.000
  CABG5 (16.7%)6 (20%)0.739
  Atrial fibrillation3 (10%)7 (23.3%)0.166
Renal function
  Good (eGFR > 60 mL/min)26 (86.7%)20 (66.7%)0.067
  Moderate (eGFR 30 - 60 mL/min)3 (10%)8 (26.7%)0.095
  Poor (eGFR < 30 mL/min)1 (3.3%)2 (6.7%)0.554
NYHA functional class
  I16 (53.3%)4 (13.3%)0.001
  II10 (33.3%)20 (66.7%)0.010
  III4 (13.3%)5 (16.7%)0.718
  IV0 (0.0%)1 (3.3%)0.313